Philip M Spanheimer

List of Publications by Year
in descending order

33	614	687363 13	610901 24
papers	citations	h-index	g-index

34	34	34	847
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Measurement of Uterine Radiation Exposure from Lymphoscintigraphy Indicates Safety of Sentinel Lymph Node Biopsy during Pregnancy. Annals of Surgical Oncology, 2009, 16, 1143-1147.	1.5	72
2	Sumoylation Pathway Is Required to Maintain the Basal Breast Cancer Subtype. Cancer Cell, 2014, 25, 748-761.	16.8	72
3	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. Journal of Clinical Oncology, 2022, 40, 96-104.	1.6	57
4	Do giant parathyroid adenomas represent a distinct clinical entity?. Surgery, 2013, 154, 714-719.	1.9	48
5	The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. American Journal of Surgery, 2013, 206, 2-7.	1.8	45
6	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Modern Pathology, 2020, 33, 1690-1701.	5.5	42
7	Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer. Clinical Cancer Research, 2014, 20, 2115-2125.	7.0	39
8	EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. Molecular Cancer Therapeutics, 2016, 15, 503-511.	4.1	31
9	Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. Annals of Surgical Oncology, 2019, 26, 2136-2143.	1.5	30
10	Distinct Pathways Regulated by RET and Estrogen Receptor in Luminal Breast Cancer Demonstrate the Biological Basis for Combination Therapy. Annals of Surgery, 2014, 259, 793-799.	4.2	27
11	Expression of the RET Proto-oncogene Is Regulated by TFAP2C in Breast Cancer Independent of the Estrogen Receptor. Annals of Surgical Oncology, 2013, 20, 2204-2212.	1.5	24
12	Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. Annals of Surgical Oncology, 2015, 22, 4287-4294.	1.5	21
13	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. Annals of Surgical Oncology, 2021, 28, 6572-6579.	1.5	18
14	High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer. Journal of Surgical Research, 2013, 184, 519-525.	1.6	12
15	Robotic proctectomy for rectal cancer: analysis of 71 patients from a single institution. International Journal of Medical Robotics and Computer Assisted Surgery, 2017, 13, e1841.	2.3	10
16	The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 2182-2190.	1.5	9
17	Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013. American Journal of Surgery, 2017, 214, 323-328.	1.8	8
18	The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment. Npj Breast Cancer, 2022, 8, 27.	5.2	7

#	Article	IF	Citations
19	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. Annals of Surgical Oncology, 2019, 26, 4423-4429.	1.5	6
20	Pathologic nodal staging for clinically node negative soft tissue sarcoma of the extremities. Journal of Surgical Oncology, 2021, 123, 1792-1800.	1.7	6
21	A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 456-462.	1.3	6
22	Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients. Breast Cancer Research and Treatment, 2021, 189, 509-520.	2.5	5
23	Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer. Npj Breast Cancer, 2022, 8, 65.	5.2	5
24	Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2â˜’ Breast Cancer. Annals of Surgical Oncology, 2022, 29, 7662-7669.	1.5	5
25	Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer. Annals of Surgical Oncology, 2022, 29, 3051-3061.	1.5	3
26	Does Angiosarcoma of the Breast Need Nodal Staging?. Journal of the American College of Surgeons, 2022, 234, 774-782.	0.5	2
27	Reply to Comment on â€œSurveillance and Intervention after Thyroid Lobectomyâ€. Annals of Surgical Oncology, 2011, 18, 309-309.	1.5	1
28	ASO Author Reflections: Malignant/Borderline Phyllodes Tumors Without Uniformly Poor Histologic Features Have an Excellent Prognosis. Annals of Surgical Oncology, 2019, 26, 619-620.	1.5	1
29	Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?. American Surgeon, 2021, , 000313482110472.	0.8	1
30	Dosimetric and Clinical Factors Associated With Breast Reconstruction Complications in Patients Receiving Postmastectomy Radiation. Practical Radiation Oncology, 2021, , .	2.1	1
31	ASO Visual Abstract:ÂSociodemographic and Clinical Predictors ofÂNeoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer. Annals of Surgical Oncology, 2022, , 1.	1.5	0
32	Abstract P3-15-01: Patients and Researchers Together (PART); a patient-centered tumor tissue collection PARTnership between patients and researchers to increase tissue donations for breast cancer research. Cancer Research, 2022, 82, P3-15-01-P3-15-01.	0.9	0
33	ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2â˜’ Breast Cancer?. Annals of Surgical Oncology, 0, , .	1.5	0